MICHAEL FLORES: Open Payments
NPI 1427503515 · LYNWOOD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$17,094 in 341 payments from 39 companies in 2025. Trend: 2023 $22,854 · 2024 $19,313 · 2025 $17,094
Food & beverage: $10,197Speaker / faculty: $2,368Travel & lodging: $1,647Speaker / faculty: $1,620Consulting: $1,261
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 33 | $2,896 |
| Dexcom, Inc. | 5 | $2,819 |
| Amgen Inc. | 31 | $2,111 |
| Medtronic, Inc. | 9 | $1,533 |
| AstraZeneca Pharmaceuticals LP | 21 | $1,151 |
| ABBVIE INC. | 40 | $1,042 |
| Ardelyx, Inc. | 14 | $770 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 27 | $556 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $522 |
| PFIZER INC. | 19 | $367 |
Products named: REZDIFFRA, DEXCOM G7 GSS (161), REPATHA, MINIMED 780G, IBSRELA, CAPLYTA, AIRSUPRA, XIFAXAN.
Industry payments across CA — which companies pay providers there.
